Ortho Regenerative Technologies Reports its Third Quarter 2021 Results

  • Total of $6.7 million raised during current fiscal year through non-brokered private placements, including more than $1.1 million from insiders and employees
  • Ortho-R designated as a Drug/Biologics combination product by the FDA
  • Ortho-R Rotator Cuff tear repair program progressing towards start of US Phase I/II clinical study in early 2021
  • Company’s shares started trading on the U.S. OTCQB under the symbol ORTIF.

MONTREAL, Dec. 18, 2020 /CNW/ –¬†Ortho Regenerative Technologies Inc. (CSE: ORTH) (OTCQB: ORTIF) (“Ortho RTI” or the “Company“), an emerging orthobiologics company¬†focused on the development of novel soft tissue repair regenerative technologies, today reported its financial results and highlights for the third quarter of 2021 ended October 31, 2020. ¬†

“During the quarter, we continued making good progress on preparing our upcoming U.S. phase I / II clinical trial for rotator cuff tears repair. The IND preparation, cGMP…

Source link